Abstract

Multi-arm multi-stage clinical trials in which more than two drugs are simultaneously investigated provide gains over separate single- or two-arm trials. In this paper we propose a generic Bayesian adaptive decision-theoretic design for multi-arm multi-stage clinical trials with K () arms. The basic idea is that after each stage a decision about continuation of the trial and accrual of patients for an additional stage is made on the basis of the expected reduction in loss. For this purpose, we define a loss function that incorporates the patient accrual costs as well as costs associated with an incorrect decision at the end of the trial. An attractive feature of our loss function is that its estimation is computationally undemanding, also when K > 2. We evaluate the frequentist operating characteristics for settings with a binary outcome and multiple experimental arms. We consider both the situation with and without a control arm. In a simulation study, we show that our design increases the probability of making a correct decision at the end of the trial as compared to nonadaptive designs and adaptive two-stage designs.

Highlights

  • Modern medicine has seen a rapid increase in the number of drugs on the market

  • We evaluated the proportion of correct decisions for the selected Bayesian decision-theoretic multi-arm multi-stage (MAMS) design under a second alternative scenario h 1⁄4 ð0:20; 0:35; 0:35Þ where both experimental arms were superior to control

  • We generalized the Bayesian adaptive decision-theoretic design for two-arm clinical trials proposed by Cheng and Shen[20] to the setting of MAMS trials with K (K ! 2) arms

Read more

Summary

Introduction

Modern medicine has seen a rapid increase in the number of drugs on the market. The efficacy of a drug is traditionally evaluated in single-arm or two-arm trials. The RECOVERY trial, for example, compares efficacy of four candidate treatments for COVID19 to a common control arm receiving usual care.[3] Trials with more than two arms typically require fewer overall resources than multiple two-arm trials and facilitate a direct comparison of drugs.[4,5,6,7] In this paper, we study trials in which one or a few drugs are selected from a set of candidate drugs. Decision making is facilitated by incorporating interim evaluations.[8,9,10] We will refer to trials in which patients are randomized over multiple arms with multiple interim evaluations as multi-arm multi-stage (MAMS) trials. MAMS typically allow early termination of ineffective arms and early identification of effective arms

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.